Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,478,808
  • Shares Outstanding, K 405,450
  • Annual Sales, $ 803,400 K
  • Annual Income, $ -747,060 K
  • 60-Month Beta 1.34
  • Price/Sales 133.90
  • Price/Cash Flow N/A
  • Price/Book 10.63
Trade MRNA with:

Options Overview Details

View History
  • Implied Volatility 70.77%
  • Historical Volatility 113.41%
  • IV Percentile 63%
  • IV Rank 25.99%
  • IV High 124.44% on 12/09/20
  • IV Low 51.93% on 06/08/21
  • Put/Call Vol Ratio 0.49
  • Today's Volume 54,641
  • Volume Avg (30-Day) 117,595
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 598,591
  • Open Int (30-Day) 631,374

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate 8.44
  • Number of Estimates 8
  • High Estimate 10.27
  • Low Estimate 5.25
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +1,323.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
221.60 +27.89%
on 11/11/21
376.65 -24.76%
on 11/29/21
+38.72 (+15.82%)
since 11/08/21
3-Month
210.96 +34.34%
on 11/05/21
464.85 -39.03%
on 09/10/21
-139.50 (-32.99%)
since 09/08/21
52-Week
102.66 +176.06%
on 12/31/20
497.49 -43.03%
on 08/10/21
+113.54 (+66.84%)
since 12/08/20

Most Recent Stories

More News
Markets Upbeat on Vaccine Efficacy Against Omicron Variant

Markets Upbeat on Vaccine Efficacy Against Omicron Variant

JNJ : 164.34 (+0.60%)
PFE : 51.40 (-0.62%)
MRK : 73.21 (+1.29%)
ILMN : 375.98 (+1.77%)
MRNA : 283.40 (+0.37%)
GME : 173.65 (-2.34%)
BNTX : 291.94 (-3.55%)
Remedies for Omicron Apparent, Markets Up Again

New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.

JNJ : 164.34 (+0.60%)
PFE : 51.40 (-0.62%)
MRK : 73.21 (+1.29%)
ILMN : 375.98 (+1.77%)
MRNA : 283.40 (+0.37%)
GME : 173.65 (-2.34%)
BNTX : 291.94 (-3.55%)
Cellarity Appoints Biopharmaceutical Executive Ian Estepan to its Board of Directors

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointment of Ian M. Estepan to its Board of Directors. Mr. Estepan...

SRPT : 86.02 (+0.81%)
AXLA : 2.64 (+7.32%)
CDAK : 14.38 (+3.08%)
DNLI : 46.16 (+4.03%)
EVLO : 8.82 (+1.38%)
FHTX : 11.54 (+6.36%)
KLDO : 3.66 (+1.67%)
MRNA : 283.40 (+0.37%)
OMGA : 17.44 (+17.05%)
RUBY : 13.43 (+2.44%)
SANA : 18.37 (+4.14%)
MCRB : 10.11 (-4.08%)
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – December 7, 2021 – USA News Group  –  Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts,...

JPM : 160.71 (-1.14%)
BIOV.CN : 0.250 (-7.41%)
BVAXF : 0.2000 (+0.10%)
MRNA : 283.40 (+0.37%)
BNTX : 291.94 (-3.55%)
PFE : 51.40 (-0.62%)
NVAX : 181.75 (-0.60%)
Vaccine Stocks Down as Omicron May Not Be Too Severe

Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.

PFE : 51.40 (-0.62%)
MRK : 73.21 (+1.29%)
MRNA : 283.40 (+0.37%)
NVAX : 181.75 (-0.60%)
BNTX : 291.94 (-3.55%)
Delta, Kohl's rise; Moderna, AST SpaceMobile fall

Stocks that traded heavily or had substantial price changes Monday:

TACO : 12.51 (+0.24%)
DAL : 38.88 (+2.21%)
BKE : 50.03 (-0.54%)
SAIC : 84.84 (+0.14%)
GCP : 31.71 (unch)
MRNA : 283.40 (+0.37%)
Stocks Recover from Omicron Selloff

Energy and consumer stocks helped Canada's main stock index rise on Monday, as oil prices jumped after ...

MRNA : 283.40 (+0.37%)
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron

The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron

REGN : 654.04 (+2.98%)
JNJ : 164.34 (+0.60%)
PFE : 51.40 (-0.62%)
MRNA : 283.40 (+0.37%)
BNTX : 291.94 (-3.55%)
5 Defensive ETF Bets as Omicron Enters the United States

Let's look at some safe ETF plays that investors can consider keeping in mind the rising concerns emanating from the new omicron variant.

MRNA : 283.40 (+0.37%)
GLD : 166.90 (+0.05%)
VIG : 167.83 (-0.12%)
QUAL : 144.26 (+0.12%)
VDC : 189.07 (-0.31%)
SPLV : 65.19 (-0.02%)
Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab

Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.

GSK : 42.68 (+0.71%)
JNJ : 164.34 (+0.60%)
MRNA : 283.40 (+0.37%)
NVAX : 181.75 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA-...

See More

Key Turning Points

3rd Resistance Point 305.52
2nd Resistance Point 296.90
1st Resistance Point 290.15
Last Price 283.40
1st Support Level 274.78
2nd Support Level 266.16
3rd Support Level 259.41

See More

52-Week High 497.49
Fibonacci 61.8% 346.66
Fibonacci 50% 300.08
Last Price 283.40
Fibonacci 38.2% 253.49
52-Week Low 102.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar